Literature DB >> 10780570

Endoscopic evaluation of gastro-esophageal reflux disease.

D Armstrong1.   

Abstract

Endoscopy is, currently, the initial investigation of choice for the investigation of gastroesophageal reflux disease (GERD) in clinical practice and clinical research. Erosion severity is predictive of a patient's response to therapy and of the likelihood of relapse after therapy. It is, therefore, important to grade the severity of erosive reflux esophagitis, particularly in the context of clinical trials. The Savary-Miller endoscopic classification system is used widely but usage and interpretation are very variable. The "MUSE" (metaplasia [M], ulceration [U], stricturing [S] and erosions [E]) classification provides clear definitions of the relevant endoscopic features, and it is based on a standardized report form, which allows the endoscopist to make a clear record of esophagitis severity. Recent studies confirm that endoscopists can identify erosions or mucosal breaks, ulcers, strictures, and metaplasia reproducibly. The "L.A." (Los Angeles) classification describes four grades of esophagitis severity (A to D), based on the extent of esophageal lesions known as "mucosal breaks," but it does not record the presence or severity of other GERD lesions. Thus, for patients with "complicated" reflux disease, the "MUSE" classification offers a more comprehensive description of esophagitis severity. Endoscopy is not universally applicable: 40 to 60 percent of patients with typical reflux symptoms do not have esophageal erosions and are now considered to have "endoscopy negative reflux disease" (ENRD). Thus, endoscopy is not the final arbiter as to a diagnosis of reflux disease, and it is not, therefore, a necessary prerequisite to therapy. Endoscopy is indicated at first presentation for patients with alarm symptoms referable to the upper gastrointestinal tract. It has also been proposed that all patients with chronic GERD should have a "once-in-a-lifetime" endoscopy; in the absence of Barrett's esophagus or other complications, no follow-up is required unless the patient's symptoms change significantly. A surveillance program with multiple biopsies should be instituted if there is evidence of Barrett's esophagus. Endoscopic evaluation should document the presence and extent of esophageal erosions using the L.A. or MUSE classification systems; complications should also be documented and may be recorded using the MUSE classification. Non-erosive changes such as erythema may be ignored on the basis of present evidence, and there are no clear data to support the use of endoscopic biopsies for the diagnosis of GERD.

Entities:  

Mesh:

Year:  1999        PMID: 10780570      PMCID: PMC2579014     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  11 in total

1.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

2.  The endoscopic assessment of esophagitis: a progress report on observer agreement.

Authors:  D Armstrong; J R Bennett; A L Blum; J Dent; F T De Dombal; J P Galmiche; L Lundell; M Margulies; J E Richter; S J Spechler; G N Tytgat; L Wallin
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

3.  The normal human esophageal mucosa: a histological reappraisal.

Authors:  W M Weinstein; E R Bogoch; K L Bowes
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

4.  Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management?

Authors:  K K Ellis; M Oehlke; M Helfand; D Lieberman
Journal:  Am J Gastroenterol       Date:  1997-09       Impact factor: 10.864

5.  Intracytoplasmic plasma proteins in distended esophageal squamous cells (balloon cells).

Authors:  J Jessurun; J H Yardley; F M Giardiello; S R Hamilton
Journal:  Mod Pathol       Date:  1988-05       Impact factor: 7.842

6.  Histological consequences of gastroesophageal reflux in man.

Authors:  F Ismail-Beigi; P F Horton; C E Pope
Journal:  Gastroenterology       Date:  1970-02       Impact factor: 22.682

7.  [Endoscopic diagnosis of oesophagitis: problems of differentiation from normal (author's transl)].

Authors:  A Schüle; H Brändli; S Pelloni; H R Koelz; W J Pirozynski; A L Blum
Journal:  Dtsch Med Wochenschr       Date:  1977-04-22       Impact factor: 0.628

8.  [Are loss of glistening of normal colour and increased friability normal aspects of the oesophagus in old age? (author's transl)].

Authors:  H Leu; A Schüle; H Brändli; S Pelloni; L Blum
Journal:  Z Gastroenterol       Date:  1978-07       Impact factor: 2.000

9.  A guide for surveillance of patients with Barrett's esophagus.

Authors:  D Provenzale; J A Kemp; S Arora; J B Wong
Journal:  Am J Gastroenterol       Date:  1994-05       Impact factor: 10.864

10.  Effect of cisapride on relapse of esophagitis. A multinational, placebo-controlled trial in patients healed with an antisecretory drug. The Italian Eurocis Trialists.

Authors:  A L Blum; B Adami; M H Bouzo; G Brandstätter; I Fumagalli; J P Galmiche; H Hebbeln; E Hentschel; W Hüttemann; E SChütz
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

View more
  28 in total

1.  Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease.

Authors:  Mogens Bove; Michael Vieth; Frank Dombrowski; Lars Ny; Magnus Ruth; Lars Lundell
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 2.  [Correct diagnosis for indication in gastroesophageal reflux disease].

Authors:  A H Hölscher; E Bollschweiler; Ch Gutschow; P Malfertheiner
Journal:  Chirurg       Date:  2005-04       Impact factor: 0.955

3.  Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls.

Authors:  A Altomare; J Ma; M P L Guarino; L Cheng; F Rieder; M Ribolsi; C Fiocchi; P Biancani; K Harnett; M Cicala
Journal:  Neurogastroenterol Motil       Date:  2012-06-26       Impact factor: 3.598

4.  Is pH Testing Necessary Before Antireflux Surgery in Patients with Endoscopic Erosive Esophagitis?

Authors:  Katrin Schwameis; Brenda Lin; Jordan Roman; Ketetha Olengue; Steve Siegal; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2017-08-25       Impact factor: 3.452

5.  Introduction into the NHS of magnetic sphincter augmentation: an innovative surgical therapy for reflux - results and challenges.

Authors:  D Prakash; B Campbell; S Wajed
Journal:  Ann R Coll Surg Engl       Date:  2018-01-24       Impact factor: 1.891

Review 6.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 7.  Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Axel Eickhoff; Johannes Schulze
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

8.  Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations.

Authors:  Luca Mastracci; Paola Spaggiari; Federica Grillo; Patrizia Zentilin; Pietro Dulbecco; Paola Ceppa; Paola Baccini; Carlo Mansi; Vincenzo Savarino; Roberto Fiocca
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

9.  Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.

Authors:  J C Y Wu; F K L Chan; J Y L Ching; W-K Leung; Y Hui; R Leong; S C S Chung; J J Y Sung
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

10.  Achalasia-Specific Quality of Life After Pneumatic Dilation or Laparoscopic Heller Myotomy With Partial Fundoplication: A Multicenter, Randomized Clinical Trial.

Authors:  Caitlin C Chrystoja; Gail E Darling; Nicholas E Diamant; Paul P Kortan; George A Tomlinson; Wayne Deitel; Audrey Laporte; Julie Takata; David R Urbach
Journal:  Am J Gastroenterol       Date:  2016-09-13       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.